These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 33234725

  • 1. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
    Zhang Z, He CZ, Qin YQ, Liao JJ, Huang ST, Mo S, Li HM, Lin JY.
    Aging (Albany NY); 2020 Nov 21; 12(23):24255-24269. PubMed ID: 33234725
    [Abstract] [Full Text] [Related]

  • 2. Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma.
    Zhu Q, Ren H, Li X, Qian B, Fan S, Hu F, Xu L, Zhai B.
    Aging (Albany NY); 2020 Nov 16; 12(22):22975-23003. PubMed ID: 33203790
    [Abstract] [Full Text] [Related]

  • 3. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M, Wang Z, Zhi X, Ding W, Xiong J, Tao T, Yang Y, Zhang H, Zi X, Zhou W, Huang G.
    Biomed Pharmacother; 2020 Sep 16; 129():110315. PubMed ID: 32554246
    [Abstract] [Full Text] [Related]

  • 4. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S, van der Helm D, Gray PC, Chen L, Klima I, Grosjean J, Burgmans MC, Farina-Sarasqueta A, Snaar-Jagalska EB, Stroka DM, Terracciano L, van Hoek B, Schaapherder AF, Osanto S, Thalmann GN, Verspaget HW, Coenraad MJ, Kruithof-de Julio M.
    J Pathol; 2018 Jul 16; 245(3):297-310. PubMed ID: 29604056
    [Abstract] [Full Text] [Related]

  • 5. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C, Dong Z, Yang C, Zhang M, Dai B, Geng L, Lu J, Yang J, Xu M.
    J Cell Mol Med; 2019 Sep 16; 23(9):6024-6033. PubMed ID: 31210410
    [Abstract] [Full Text] [Related]

  • 6. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 7. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
    Gao L, Morine Y, Yamada S, Saito Y, Ikemoto T, Tokuda K, Takasu C, Miyazaki K, Shimada M.
    PLoS One; 2021 Oct 06; 16(9):e0256755. PubMed ID: 34473785
    [Abstract] [Full Text] [Related]

  • 8. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL, Cheng CL, Li MY, Yang SL, Hu BG, Chong CCN, Chan SL, Ren J, Chen GG, Lai PBS.
    Cell Death Dis; 2018 Aug 28; 9(9):852. PubMed ID: 30154433
    [Abstract] [Full Text] [Related]

  • 9. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
    Tang S, Tan G, Jiang X, Han P, Zhai B, Dong X, Qiao H, Jiang H, Sun X.
    Oncotarget; 2016 Nov 08; 7(45):73257-73269. PubMed ID: 27689326
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, Luo Y, Yao C, Qian C.
    Cancer Lett; 2016 Feb 28; 371(2):171-81. PubMed ID: 26655273
    [Abstract] [Full Text] [Related]

  • 11. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating Reelin gene expression.
    Wang S, Liu D, Wei H, Hua Y, Shi G, Qiao J.
    Bioengineered; 2022 Feb 28; 13(2):2272-2284. PubMed ID: 35034536
    [Abstract] [Full Text] [Related]

  • 12. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
    Lin H, Zhang R, Wu W, Lei L.
    Cancer Genet; 2020 Jul 28; 245():27-34. PubMed ID: 32559715
    [Abstract] [Full Text] [Related]

  • 13. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q, Zheng B, Meng S, Xu Y, Guo J, Chen LJ, Xiao J, Zhang W, Tan ZR, Tang J, Chen L, Chen Y.
    Biomed Pharmacother; 2019 Jun 28; 114():108864. PubMed ID: 30981107
    [Abstract] [Full Text] [Related]

  • 14. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
    Li TT, Mou J, Pan YJ, Huo FC, Du WQ, Liang J, Wang Y, Zhang LS, Pei DS.
    J Biomed Sci; 2021 Aug 02; 28(1):56. PubMed ID: 34340705
    [Abstract] [Full Text] [Related]

  • 15. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar 02; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 16. PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.
    Lin JC, Yang PM, Liu TP.
    Int J Mol Sci; 2021 May 29; 22(11):. PubMed ID: 34072570
    [Abstract] [Full Text] [Related]

  • 17. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
    Kumar M, Kaur R, Kanthaje S, Dhiman RK, Chakraborti A.
    J Cancer Res Clin Oncol; 2023 Aug 29; 149(9):5823-5839. PubMed ID: 36583742
    [Abstract] [Full Text] [Related]

  • 18. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
    Wang P, Jiang Z, Liu X, Yu K, Wang C, Li H, Zhong L.
    Cancer Med; 2020 Oct 29; 9(19):6972-6983. PubMed ID: 32779397
    [Abstract] [Full Text] [Related]

  • 19. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G, Zhao W, Wang H, Qiu G, Jiang Z, Wei G, Li X.
    Med Sci Monit; 2019 Sep 25; 25():7209-7217. PubMed ID: 31553714
    [Abstract] [Full Text] [Related]

  • 20. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT, Shu ZY, Jiang JH, Xie QF, Zheng SS.
    Hepatobiliary Pancreat Dis Int; 2020 Dec 25; 19(6):547-554. PubMed ID: 33051131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.